GB2279077B - Therapeutic compositions comprising recombinant antibodies specific for the TNFalpha - Google Patents

Therapeutic compositions comprising recombinant antibodies specific for the TNFalpha

Info

Publication number: GB2279077B
Authority: GB; United Kingdom
Prior art keywords: tnfalpha; antibodies specific; therapeutic compositions; recombinant antibodies; recombinant
Prior art date: 1990-12-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Inventor

Mark William Bodmer

John Spencer Emtage

Diljeet Singh Athwal

John Robert Adair

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Celltech R&D Ltd

Original Assignee

Celltech Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-12-21

Filing date

1991-12-20

Publication date

1995-06-14

1990-12-21Priority claimed from PCT/GB1990/002017external-prioritypatent/WO1991009967A1/en

1991-05-03Priority claimed from GB919109645Aexternal-prioritypatent/GB9109645D0/en

1991-12-20Application filed by Celltech LtdfiledCriticalCelltech Ltd

1994-09-21Publication of GB9415380D0publicationCriticalpatent/GB9415380D0/en

1994-12-21Publication of GB2279077ApublicationCriticalpatent/GB2279077A/en

1995-06-14Application grantedgrantedCritical

1995-06-14Publication of GB2279077BpublicationCriticalpatent/GB2279077B/en

2011-12-20Anticipated expirationlegal-statusCritical

StatusExpired - Lifetimelegal-statusCriticalCurrent

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Life Sciences & Earth Sciences (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

GB9415380A1990-12-211991-12-20Therapeutic compositions comprising recombinant antibodies specific for the TNFalphaExpired - LifetimeGB2279077B (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
PCT/GB1990/002017WO1991009967A1 (en)	1989-12-21	1990-12-21	Humanised antibodies
GB919109645AGB9109645D0 (en)	1991-05-03	1991-05-03	Recombinant antibodies
GB9217880AGB2257145B (en)	1990-12-21	1991-12-20	Recombinant antibodies specific for TNFalpha

Publications (3)

Publication Number	Publication Date
GB9415380D0 GB9415380D0 (en)	1994-09-21
GB2279077A GB2279077A (en)	1994-12-21
GB2279077Btrue GB2279077B (en)	1995-06-14

Family

ID=26298838

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
GB9415380AExpired - LifetimeGB2279077B (en)	1990-12-21	1991-12-20	Therapeutic compositions comprising recombinant antibodies specific for the TNFalpha

Country Status (1)

Country	Link
GB (1)	GB2279077B (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8197813B2 (en)	1996-02-09	2012-06-12	Abbott Biotechnology Ltd.	Human antibodies that bind human TNFα
US8206714B2 (en)	1996-02-09	2012-06-26	Abbott Biotechnology Ltd.	Methods for treating rheumatoid arthritis using human antibodies that bind human TNFa
US8231876B2 (en)	2006-04-05	2012-07-31	Abbott Biotechnology Ltd.	Purified antibody composition
US8715664B2 (en)	2005-05-16	2014-05-06	Abbvie Biotechnology Ltd.	Use of human TNFα antibodies for treatment of erosive polyarthritis
US8846046B2 (en)	2002-10-24	2014-09-30	Abbvie Biotechnology Ltd.	Low dose methods for treating disorders in which TNFα activity is detrimental
US8889136B2 (en)	2004-04-09	2014-11-18	Abbvie Biotechnology Ltd.	Multiple-variable dose regimen for treating TNFα-related disorders
US8999337B2 (en)	2007-06-11	2015-04-07	Abbvie Biotechnology Ltd.	Methods for treating juvenile idiopathic arthritis by inhibition of TNFα
US9399061B2 (en)	2006-04-10	2016-07-26	Abbvie Biotechnology Ltd	Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2385745C (en)	2001-06-08	2015-02-17	Abbott Laboratories (Bermuda) Ltd.	Methods of administering anti-tnf.alpha. antibodies
WO2009032128A1 (en)	2007-08-28	2009-03-12	Abbott Biotechnology Ltd.	Compositions and methods comprising binding proteins for adalimumab
RU2537139C2 (en)	2008-01-15	2014-12-27	Эбботт Гмбх Унд Ко.Кг	Protein powder compositions and methods for preparing them
US9062106B2 (en)	2011-04-27	2015-06-23	Abbvie Inc.	Methods for controlling the galactosylation profile of recombinantly-expressed proteins
WO2013158273A1 (en)	2012-04-20	2013-10-24	Abbvie Inc.	Methods to modulate c-terminal lysine variant distribution
US9067990B2 (en)	2013-03-14	2015-06-30	Abbvie, Inc.	Protein purification using displacement chromatography
US9334319B2 (en)	2012-04-20	2016-05-10	Abbvie Inc.	Low acidic species compositions
WO2013176754A1 (en)	2012-05-24	2013-11-28	Abbvie Inc.	Novel purification of antibodies using hydrophobic interaction chromatography
US9512214B2 (en)	2012-09-02	2016-12-06	Abbvie, Inc.	Methods to control protein heterogeneity
HK1211981A1 (en)	2012-09-02	2016-06-03	Abbvie Inc.	Methods to control protein heterogeneity
WO2014143205A1 (en)	2013-03-12	2014-09-18	Abbvie Inc.	Human antibodies that bind human tnf-alpha and methods of preparing the same
US9017687B1 (en)	2013-10-18	2015-04-28	Abbvie, Inc.	Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014159579A1 (en)	2013-03-14	2014-10-02	Abbvie Inc.	MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
WO2014151878A2 (en)	2013-03-14	2014-09-25	Abbvie Inc.	Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9598667B2 (en)	2013-10-04	2017-03-21	Abbvie Inc.	Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US8946395B1 (en)	2013-10-18	2015-02-03	Abbvie Inc.	Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en)	2013-10-18	2015-11-10	Abbvie, Inc.	Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en)	2013-10-18	2015-07-21	Abbvie, Inc.	Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en)	2013-11-15	2015-05-21	Abbvie, Inc.	Glycoengineered binding protein compositions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1990001950A1 (en)*	1988-08-19	1990-03-08	Celltech Limited	Pharmaceutical products for anti-neoplastic therapy
EP0380068A1 (en)*	1989-01-24	1990-08-01	Miles Inc.	An expression system for production of chimeric monoclonal antibodies

1991
- 1991-12-20GBGB9415380Apatent/GB2279077B/ennot_activeExpired - Lifetime

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1990001950A1 (en)*	1988-08-19	1990-03-08	Celltech Limited	Pharmaceutical products for anti-neoplastic therapy
EP0380068A1 (en)*	1989-01-24	1990-08-01	Miles Inc.	An expression system for production of chimeric monoclonal antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J.Cell.Biochem.Suppl. 1989,0(13 Part A),96,Abs.A342*

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8753633B2 (en)	1996-02-09	2014-06-17	Abbvie Biotechnology Ltd.	Human antibodies that bind human TNFα
US8206714B2 (en)	1996-02-09	2012-06-26	Abbott Biotechnology Ltd.	Methods for treating rheumatoid arthritis using human antibodies that bind human TNFa
US8197813B2 (en)	1996-02-09	2012-06-12	Abbott Biotechnology Ltd.	Human antibodies that bind human TNFα
US8372401B2 (en)	1996-02-09	2013-02-12	Abbott Biotechnology Ltd.	Human antibodies that bind human TNFα
US8414894B2 (en)	1996-02-09	2013-04-09	Abbott Biotechnology Ltd.	Human antibodies that bind human TNFα and methods of using same
US8906373B2 (en)	2002-07-19	2014-12-09	Abbvie Biotechnology Ltd.	Use of TNF-alpha inhibitor for treatment of psoriasis
US8846046B2 (en)	2002-10-24	2014-09-30	Abbvie Biotechnology Ltd.	Low dose methods for treating disorders in which TNFα activity is detrimental
US8961974B2 (en)	2004-04-09	2015-02-24	Abbvie Biotechnology Ltd.	Multiple-variable dose regimen for treating TNFα-related disorders
US9499615B2 (en)	2004-04-09	2016-11-22	Abbvie Biotechnology Ltd	Multiple-variable dose regimen for treating idiopathic inflammatory bowel disease
US8889136B2 (en)	2004-04-09	2014-11-18	Abbvie Biotechnology Ltd.	Multiple-variable dose regimen for treating TNFα-related disorders
US9187559B2 (en)	2004-04-09	2015-11-17	Abbvie Biotechnology Ltd	Multiple-variable dose regimen for treating idiopathic inflammatory bowel disease
US8986693B1 (en)	2004-04-09	2015-03-24	Abbvie Biotechnology Ltd.	Use of TNFα inhibitor for treatment of psoriasis
US8961973B2 (en)	2004-04-09	2015-02-24	Abbvie Biotechnology Ltd.	Multiple-variable dose regimen for treating TNFα-related disorders
US8808700B1 (en)	2005-05-16	2014-08-19	Abbvie Biotechnology Ltd.	Use of TNF alpha inhibitor for treatment of erosive polyarthritis
US8715664B2 (en)	2005-05-16	2014-05-06	Abbvie Biotechnology Ltd.	Use of human TNFα antibodies for treatment of erosive polyarthritis
US8916153B2 (en)	2006-04-05	2014-12-23	Abbvie Biotechnology Ltd.	Purified antibody composition
US8906372B2 (en)	2006-04-05	2014-12-09	Abbvie Biotechnology Ltd.	Purified antibody composition
US8231876B2 (en)	2006-04-05	2012-07-31	Abbott Biotechnology Ltd.	Purified antibody composition
US9096666B2 (en)	2006-04-05	2015-08-04	Abbvie Biotechnology Ltd	Purified antibody composition
US9102723B2 (en)	2006-04-05	2015-08-11	Abbvie Biotechnology Ltd	Purified antibody composition
US8895009B2 (en)	2006-04-05	2014-11-25	Abbvie Biotechnology Ltd.	Purified antibody composition
US8883156B2 (en)	2006-04-05	2014-11-11	Abbvie Biotechnology Ltd.	Purified antibody composition
US9399061B2 (en)	2006-04-10	2016-07-26	Abbvie Biotechnology Ltd	Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
US8999337B2 (en)	2007-06-11	2015-04-07	Abbvie Biotechnology Ltd.	Methods for treating juvenile idiopathic arthritis by inhibition of TNFα

Also Published As

Publication number	Publication date
GB2279077A (en)	1994-12-21
GB9415380D0 (en)	1994-09-21

Publication	Publication Date	Title
GB2279077B (en)	1995-06-14	Therapeutic compositions comprising recombinant antibodies specific for the TNFalpha
IL99363A0 (en)	1992-08-18	Pharmaceutical compositions comprising homoconjugated monoclonal antibodies
GB9026065D0 (en)	1991-01-16	Composition
ZA911279B (en)	1991-10-30	Novel protein compositions
GB9021546D0 (en)	1990-11-21	Novel composition
EP0438312A3 (en)	1992-07-01	Recombinant human anti-cd18 antibodies
IL97005A0 (en)	1992-03-29	Recombinant human anti-cd18 antibodies
EP0448099A3 (en)	1992-08-19	Novel peptides
EP0445659A3 (en)	1992-11-25	Hair-set composition
GB9006537D0 (en)	1990-05-23	Composition
EP0459608A3 (en)	1993-01-20	Photo-curable composition
GB9027728D0 (en)	1991-02-13	Novel protein
GB9223676D0 (en)	1993-01-06	Modified antibodies
EP0437297A3 (en)	1992-07-08	Curing compositions
EP0449796A3 (en)	1992-06-10	Polyurethane-terpolymer blends
EP0474056A3 (en)	1992-07-08	Bellows
IE891280L (en)	1989-10-21	Recombinant antibodies
GB9013419D0 (en)	1990-08-08	Antibodies
GB9007065D0 (en)	1990-05-30	Recombinant protein receptor
IE870536L (en)	1987-09-04	Compositions comprising monoclonal antibodies
RU1785672C (en)	1993-01-07	Composition for cryotherapy
GB9420892D0 (en)	1994-11-30	Recombinant antibodies
ZA91346B (en)	1991-11-27	Recombinant human anti-cd18 antibodies
GB9027490D0 (en)	1991-02-06	Curing compositions
GB9024604D0 (en)	1991-01-02	Composition

Legal Events

Date	Code	Title	Description
2012-01-11	PE20	Patent expired after termination of 20 years	Expiry date:20111219

Movatterモバイル変換